| 【行业研究】中国互联网行业 – 分析师路演反馈：行百里者半九十 |
| 【Company Research】SF Holding (002352 CH) – Core net profit in 4Q21 below expectation but recovery trend will continue |
| 【Company Research】ZTE (763 HK) – ZTE finished 2021 with good results; Positive potentials could materialize ahead |
| 【Fixed Income Research】HPDLF: Another big 4 is expected to be appointed soon |
| 【Company Research】Willsemi (603501 CH) – Solid 4Q; Well poised to embrace 2022. Reiterate BUY |
| 【Sector Research】Auto and China Property Sector – NEV swiping right for hip malls |
| 【Company Research】CR Beer (291 HK) – Profit alert in line with us; still our sector top buy |
| 【Company Research】Haidilao (6862 HK) – Reforms on track, but hindered by pandemic |
| 【Company Research】Shengyi Technology (600183 CH) – Weaker 4Q21 with limited pricing upside in 2022; D/G to HOLD |
| 【Company Research】I-Mab BioPharma (IMAB US) – A significantly undervalued biotech company with solid pipeline assets |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
